Skip to main content
Fig. 2 | Biology Direct

Fig. 2

From: RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2

Fig. 2

RARRES1 was downregulated in HCC tissues and suppressing RARRES1 decreased HCC cell sensitivity to lenvatinib. (A-D) RT-qPCR and western blot assays were used to detect the knockdown efficiency of three genes in Huh7 and SKHEP1 cells. (E–F) Sensitivity to lenvatinib in siPLAAT4/siRARRES1/siHMGCS2-treated Huh7 and SKHEP1 cells, determined by CCK-8 assay. (G) HuH7 and SKHEP1 cells were treated with siCtrl + vehicle, siRARRES1 + vehicle, siCtrl + lenvatinib, and siRARRES1 + lenvatinib for 24, 48, 72 and 96 h and cell viability determined by CCK-8 assay. (H) Results of cell colony formation assay. (I) HuH7 and SKHEP1 cells apoptosis after treatment with siRARRES1 and/or lenvatinib, determined by flow cytometry. (J–K) RT-qPCR and western blot assays were used to examine RARRES1 mRNA and protein levels in 12 matched HCC and adjacent normal liver tissue samples. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us